Literature DB >> 15879043

Multiple sclerosis: diagnosis and the management of acute relapses.

S M Leary1, B Porter, A J Thompson.   

Abstract

Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system that may result in a wide range of neurological symptoms and accumulating disability. Its course is unpredictable resulting in a changing pattern of clinical need. Diagnostic criteria for multiple sclerosis require objective evidence for dissemination in space and time. The diagnostic and management process should follow good practice guidelines with the person at the centre of the process. Appropriate support and information should be available from the time of diagnosis. Continuing education is key in enabling the person to actively participate in their management. In the event of an acute relapse the person should have direct access to the most appropriate local service. Provided medical causes have been excluded, corticosteroid treatment to hasten the recovery from the relapse should be considered. Management of an acute relapse should be comprehensive addressing any medical, functional, or psychosocial sequelae.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879043      PMCID: PMC1743263          DOI: 10.1136/pgmj.2004.029413

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  53 in total

1.  A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis.

Authors:  A E Miller; L A Morgante; L Y Buchwald; S M Nutile; P K Coyle; L B Krupp; C A Doscher; F D Lublin; R L Knobler; F Trantas; L Kelley; C R Smith; N La Rocca; S Lopez
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

Review 2.  Primary progressive multiple sclerosis.

Authors:  A J Thompson; C H Polman; D H Miller; W I McDonald; B Brochet; X Filippi M Montalban; J De Sá
Journal:  Brain       Date:  1997-06       Impact factor: 13.501

3.  Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK.

Authors:  G V McDonnell; S A Hawkins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

4.  Effective physician-patient communication and health outcomes: a review.

Authors:  M A Stewart
Journal:  CMAJ       Date:  1995-05-01       Impact factor: 8.262

5.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

6.  Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.

Authors:  D Barnes; R A Hughes; R W Morris; O Wade-Jones; P Brown; T Britton; D A Francis; G D Perkin; P Rudge; M Swash; H Katifi; S Farmer; J Frankel
Journal:  Lancet       Date:  1997-03-29       Impact factor: 79.321

7.  Cost analysis of methylprednisolone treatment of multiple sclerosis patients.

Authors:  L S Robson; C Bain; S Beck; S Guthrie; P C Coyte; P O'Connor
Journal:  Can J Neurol Sci       Date:  1998-08       Impact factor: 2.104

8.  The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group.

Authors:  R W Beck; P A Cleary; J D Trobe; D I Kaufman; M J Kupersmith; D W Paty; C H Brown
Journal:  N Engl J Med       Date:  1993-12-09       Impact factor: 91.245

9.  Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.

Authors:  S M Alam; T Kyriakides; M Lawden; P K Newman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

10.  Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

Authors:  C Confavreux; M Hutchinson; M M Hours; P Cortinovis-Tourniaire; T Moreau
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

View more
  19 in total

Review 1.  Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis.

Authors:  Rosa C Lucchetta; Fernanda S Tonin; Helena H L Borba; Letícia P Leonart; Vinicius L Ferreira; Aline F Bonetti; Bruno S Riveros; Jefferson Becker; Roberto Pontarolo; Fernando Fernandez-Llimós; Astrid Wiens
Journal:  CNS Drugs       Date:  2018-09       Impact factor: 5.749

2.  Effects of physical comorbidities on disability progression in multiple sclerosis.

Authors:  Tingting Zhang; Helen Tremlett; Feng Zhu; Elaine Kingwell; John D Fisk; Virender Bhan; Trudy Campbell; Karen Stadnyk; Robert Carruthers; Christina Wolfson; Sharon Warren; Ruth Ann Marrie
Journal:  Neurology       Date:  2018-01-03       Impact factor: 9.910

3.  Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.

Authors:  Maria Di Gregorio; Lorenzo Gaetani; Paolo Eusebi; Piero Floridi; Antonella Picchioni; Giovanni Rosi; Andrea Mancini; Chiara Floridi; Francesca Baschieri; Lucia Gentili; Paola Sarchielli; Paolo Calabresi; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2018-01-11       Impact factor: 4.849

4.  Multiple sclerosis following a spinal cord injury: a rare and unfortunate case.

Authors:  R S Salinas-González; L Rodríguez-Sánchez; R A Pelayo-Vergara; J Benito-Penalva
Journal:  Spinal Cord Ser Cases       Date:  2016-01-07

5.  Characterizing the time course of cerebrovascular reactivity in multiple sclerosis.

Authors:  John A Lincoln; Khader M Hasan; Refaat E Gabr; Jerry S Wolinsky
Journal:  J Neuroimaging       Date:  2022-02-14       Impact factor: 2.324

6.  Vitamin D-binding protein in cerebrospinal fluid is associated with multiple sclerosis progression.

Authors:  Mingchong Yang; Zhaoyu Qin; Yanyan Zhu; Yun Li; Yanjiang Qin; Yongsheng Jing; Shilian Liu
Journal:  Mol Neurobiol       Date:  2013-01-22       Impact factor: 5.590

7.  The feasibility of collecting information from people with Multiple Sclerosis for the UK MS Register via a web portal: characterising a cohort of people with MS.

Authors:  David V Ford; Kerina H Jones; Rod M Middleton; Hazel Lockhart-Jones; Inocencio Dc Maramba; Gareth J Noble; Lisa A Osborne; Ronan A Lyons
Journal:  BMC Med Inform Decis Mak       Date:  2012-07-18       Impact factor: 2.796

8.  Assessing relapse in multiple sclerosis questionnaire: results of a pilot study.

Authors:  Amy Perrin Ross; Alona Williamson; Jennifer Smrtka; Tracy Flemming Tracy; Carol Saunders; Constance Easterling; John Niewoehner; Nicole Mutschler
Journal:  Mult Scler Int       Date:  2013-05-26

9.  Pinocembrin Promotes OPC Differentiation and Remyelination via the mTOR Signaling Pathway.

Authors:  Qi Shao; Ming Zhao; Wenwen Pei; Yingyan Pu; Mingdong Liu; Weili Liu; Zhongwang Yu; Kefu Chen; Hong Liu; Benqiang Deng; Li Cao
Journal:  Neurosci Bull       Date:  2021-06-06       Impact factor: 5.271

Review 10.  Symptomatic management in multiple sclerosis.

Authors:  Pushkar Shah
Journal:  Ann Indian Acad Neurol       Date:  2015-09       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.